Microparticles for diagnosis of graft-versus-host disease after allogeneic stem transplantation
Background. - The differentiation between acute graft-versus-host disease (aGvHD) and infection is still a clinical challenge in patients after allogeneic hematopoietic stem-cell transplantation (HSCT). Definitive diagnosis is based on histologic findings, but a simple blood test for differentiation...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 27, 2011
|
| In: |
Transplantation
Year: 2011, Volume: 92, Issue: 2, Pages: 244-250 |
| ISSN: | 1534-6080 |
| DOI: | 10.1097/TP.0b013e318221d3e9 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/TP.0b013e318221d3e9 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/transplantjournal/Fulltext/2011/07270/Microparticles_for_Diagnosis_of_Graft_Versus_Host.20.aspx 
|
| Author Notes: | Andreas Rank, Rienk Nieuwland, Bettina Toth, Verena Pihusch, Ruth Delker, Erhard Hiller, Hans-Jochem Kolb, and Rudolf Pihusch |
| Summary: | Background. - The differentiation between acute graft-versus-host disease (aGvHD) and infection is still a clinical challenge in patients after allogeneic hematopoietic stem-cell transplantation (HSCT). Definitive diagnosis is based on histologic findings, but a simple blood test for differentiation is missing. - Methods. - In a prospective study, we measured the plasma levels of erythrocyte-derived microparticles (EryMP) in 19 recipients during HSCT. Microparticles were isolated by differential centrifugation, double stained for glycophorin A (CD235) and annexin V, and analyzed by flow cytometry. - Results. - Eight patients developed aGvHD (42%), 15 patients developed infectious complications (79%), and two patients developed microangiopathic hemolytic anemia (11%). The levels of EryMP, as measured before conditioning therapy (535×106/L in median), were not affected by total body irradiation, high-dose chemotherapy, or in vivo T-cell depletion. EryMP levels were unaffected in uncomplicated patients during aplasia (522×106/L in median; P=0.394) or after engraftment (480×106/L in median; P=0.594) and in patients with infectious complications or sepsis (586×106/L in median; P=0.606). In contrast, in patients who developed aGvHD after HSCT, a 1.7-fold increase in the plasma levels of EryMP was observed (880×106/L in median; P<0.001 compared with the time before therapy and P=0.015 compared with patients with infections or sepsis). - Conclusion. - Increased plasma levels of EryMP are present in patients who develop aGvHD but not in patients who develop infection or sepsis after HSCT. Therefore, EryMP are a potential, novel, blood marker that may be helpful in the diagnosis of this common complication after HSCT. |
|---|---|
| Item Description: | Gesehen am 12.09.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1534-6080 |
| DOI: | 10.1097/TP.0b013e318221d3e9 |